Financials Island Pharmaceuticals Limited
Equities
ILA
AU0000138869
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4200 AUD | +1.20% |
|
+13.51% | -2.33% |
| 04/03 | Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold | FI |
| 04/03 | Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19% | MT |
Projected Income Statement: Island Pharmaceuticals Limited
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 0.0005 |
| Change | - | - | - | - | - | - |
| EBITDA 1 | - | -2.818 | - | -6.5 | -18.8 | 420.8 |
| Change | - | - | - | - | -189.23% | 2,338.3% |
| EBIT 1 | - | -2.818 | - | -6.5 | -18.8 | 420.8 |
| Change | - | - | - | - | -189.23% | 2,338.3% |
| Interest Paid | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -2.864 | - | - | - | - |
| Change | - | - | - | - | - | - |
| Net income 1 | -2.83 | -2.864 | -3.92 | -4.6 | -13.2 | 294.7 |
| Change | - | -1.2% | -36.86% | -17.34% | -186.96% | 2,332.58% |
| Announcement Date | 30/8/23 | 29/8/24 | 28/8/25 | - | - | - |
1AUD in Million
Estimates
Forecast Balance Sheet: Island Pharmaceuticals Limited
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | -1.24 | - | 0.6 | -18.2 | 258 |
| Change | - | - | - | - | -3,133.33% | 1,517.58% |
| Announcement Date | 30/8/23 | 29/8/24 | 28/8/25 | - | - | - |
1AUD in Million
Estimates
Cash Flow Forecast: Island Pharmaceuticals Limited
| Fiscal Period: June | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | - | - | - |
| Change | - | - | - |
| Free Cash Flow (FCF) 1 | -8.3 | -18.8 | 275.8 |
| Change | - | -126.51% | 1,567.02% |
| Announcement Date | - | - | - |
1AUD in Million
Estimates
Forecast Financial Ratios: Island Pharmaceuticals Limited
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
Profitability | ||||||
| EBITDA Margin (%) | - | - | - | - | - | 84,160,000% |
| EBIT Margin (%) | - | - | - | - | - | 84,160,000% |
| EBT Margin (%) | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | 58,940,000% |
| FCF margin (%) | - | - | - | - | - | 55,160,000% |
| FCF / Net Income (%) | - | - | - | 180.43% | 142.42% | 93.59% |
Profitability | ||||||
| ROA | - | - | - | -129.3% | 473.7% | 297.2% |
| ROE | - | - | - | -93.8% | - | 215.5% |
Financial Health | ||||||
| Leverage (Debt/EBITDA) | - | - | - | -0.09x | - | 0.61x |
| Debt / Free cash flow | - | - | - | -0.07x | - | 0.93x |
Capital Intensity | ||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - |
Items per share | ||||||
| Cash flow per share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 0.012 | - | - | - | - |
| Change | - | - | - | - | - | - |
| EPS 1 | -0.0323 | -0.0317 | -0.0226 | -0.0177 | -0.047 | 1.011 |
| Change | - | 1.89% | 28.71% | 21.68% | -165.54% | 2,250.21% |
| Nbr of stocks (in thousands) | 81,268 | 126,767 | 236,093 | 294,767 | 294,767 | 294,767 |
| Announcement Date | 30/8/23 | 29/8/24 | 28/8/25 | - | - | - |
1AUD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E ratio | -23.7x | -8.94x |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ILA Stock
- Financials Island Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition